Aayushi Paresh Pratap

Aayushi Pratap

Freelance writer

Aayushi Pratap is a New York-based health and science journalist and an alum of Columbia Journalism School. Reach her on LinkedIn.

Women are already underrepresented in clinical trials; the new abortion and IVF laws could make it worse.
The entry of new players and new approaches into the ATTR-CM space could help bring down the cost of treatment, experts say.
If approved, ensifentrine would be the first non-steroidal, anti-inflammatory drug for patients with chronic obstructive pulmonary disease, offering an option with potentially fewer side effects.
While NK cell therapies can potentially avoid the serious side effects sometimes seen with CAR T cell therapies, experts say durability may stall their path to the market.
A string of rejections prompt some to look beyond research roles in the biopharma industry as they seek to launch a career.
The newly proposed salary increase for NIH-funded postdocs would not make the positions competitive with what the industry offers, experts said.
Once dormant due to a lack of commercial success and drug side effects, the radiopharmaceutical space is gaining momentum in the form of increased investment and scientific advances.
Even before its billionaire owner made recent headlines by endorsing an antisemitic post and hurling an expletive at advertisers, biopharma companies had begun to find different uses for their advertisement budgets.
Although looking for candidates on platforms like LinkedIn continues to be the norm, some headhunters are also combing Google Scholar and PubMed for authors with relevant skills.
A recent report by Tufts Medical Center reveals impressive approval rates for durable cell and gene therapies, but experts urge caution over persistent safety and accessibility concerns.